Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Conditions
Brief summary
This phase Ib/II trial studies the side effects and best dose of toll-like receptor 9 (TLR9) agonist SD-101 when given together with ibrutinib and radiation therapy and to see how well they work in treating patients with Low Grade Follicular Lymphoma, Marginal Zone Lymphoma, or Mantle Cell Lymphoma that has come back after a period of improvement or no longer responds to treatment. Immunostimulants such as TLR9 agonist SD-101 may increase the ability of the immune system to fight infection and disease. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving TLR9 agonist SD-101 with ibrutinib and radiation therapy may induce an immune response and prolong anti-tumor response.
Detailed description
Primary Objective: Phase 1b: - To determine the recommended phase 2 dose (RP2D) of intratumoral SD 101 in combination with ibrutinib and radiation in subjects with relapsed or refractory B cell lymphoma . - To determine the safety and tolerability of SD 101 in combination with ibrutinib and radiation in subjects with relapsed or refractory B cell lymphoma Phase 2: -To evaluate the efficacy of intratumoral SD 101 in combination with ibrutinib and radiation in subjects with relapsed or refractory B cell lymphoma by assessing overall response rate Secondary Objective: Phase 2: - To evaluate progression free survival after treatment with intratumoral SD 101 in combination with ibrutinib and radiation in subjects with relapsed or refractory B cell lymphoma \- To evaluate the induction of tumor-specific immune responses by treatment with intratumoral SD-101 in combination with ibrutinib and radiation in patients with relapsed or refractory B cell lymphoma
Interventions
DRUGIbrutinib
Given PO
RADIATIONRadiation Therapy
Undergo radiation therapy
Given IT
Sponsors
Janssen, LP
National Cancer Institute (NCI)
The Leukemia and Lymphoma Society
Rising Tide Foundation
Robert Lowsky
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Biopsy confirmed Grade 1 or 2, or 3A follicular lymphoma; mantle cell lymphoma; or marginal zone lymphoma. Subjects must have relapsed from or are refractory to prior therapy. * Subjects must have at least one site of disease that is accessible for intratumoral injection of SD 101 (diameter ≥ 10mm), percutaneously. * Subjects must have at least one site of measurable disease (see Section 10.2.2 for definition of measurable disease) other than the injection site which is not included in the radiation field. * ECOG Performance Status of 0 or 1 * Subjects must be 18 years of age or older. * Required values for initial laboratory tests: 1. Absolute neutrophil count (ANC) ≥ 1000/mm3 independent of growth factor support 2. Platelets: ≥ 100,000/mm3 or ≥ 50,000/mm3 if bone marrow involvement independent of transfusion support in either situation 3. Hemoglobin: ≥ 8 g/dL (may be transfused) 4. Creatinine: Creatinine clearance \> 25 mL/min 5. AST/ALT: ≤ 3 x ULN 6. Bilirubin: ≤ 1.5 x ULN (except for subjects with Gilbert's Syndrome or of non hepatic origin) * Must be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, and 8 weeks since any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatment. * Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug. * Women of childbearing potential must have a negative serum (beta human chorionic gonadotropin \[β-hCG\]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study. * Life expectancy greater than 4 months. * Able to comply with the treatment schedule. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Autoimmune disease requiring treatment within the last 5 years including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjӧgren's syndrome, autoimmune thrombocytopenia, uveitis, or other if clinically significant * Major surgery or a wound that has not fully healed within 4 weeks of enrollment. * History of stroke or intracranial hemorrhage within 6 months prior to enrollment. * Requires anticoagulation with warfarin or equivalent vitamin K antagonists. * Requires chronic treatment with strong CYP3A inhibitors. * Vaccinated with live, attenuated vaccines within 4 weeks of enrollment. * Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or active Hepatitis B Virus infection or any uncontrolled active systemic infection. * Known CNS lymphoma. * Subjects with a history of prior malignancy with the exception of non melanoma skin cancer, carcinoma in situ of the cervix, in situ carcinoma of the bladder, stage 1 prostate cancer that does not require treatment, or other malignancy that has undergone potentially curative therapy with no evidence of disease for the last \> 2 years and that is deemed by the investigator to be a low risk for recurrence. * History of allergic reactions attributed to compounds of similar composition to SD 101 or ibrutinib * Treatment with an immunosuppressive regimen of corticosteroids or other immunosuppressive medication (eg, methotrexate, rapamycin) within 30 days of study treatment. Note: subjects may take up to 5 mg of prednisone or equivalent daily. Topical and inhaled corticosteroids in standard doses are allowed. * Significant cardiovascular disease (ie, NYHA class 3 congestive heart failure; myocardial infarction with the past 6 months; unstable angina; coronary angioplasty with the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias). * Pregnant or breast feeding. * Any other medical history, including laboratory results, deemed by the investigator to be likely to interfere with their participation in the study, or to interfere with the interpretation of the results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) | Up to 24 months | Dose-limiting toxicity was continuously throughout the trial. Adverse event information was collected at each visit. Safety labs were collected on week 2, 4, 6, 12 and every 12 weeks thereafter until the final study visit. |
| Tumor Response Rates (Phase II) | Up to 24 months | Tumor response rate of intratumoral SD 101 in combination with ibrutinib and radiation in subjects will be assessed. Tumor response rates (complete response, partial response) will be calculated based on the Lugano classification for low-grade B-cell lymphomas. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (Phase II) | Up to 24 months | Progression free Survival is defined as the time elapsed between treatment initiation (Day 1) and tumor progression or death from any cause. Progression will be defined using the Lugano Classification. This outcome will be measured on any individual who has received at least one intratumoral injection of SD 101 at the recommended phase 2 dose level. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Phase 1b -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) Patients underwent radiation therapy on days 1 and 2. Within 12 hours of the completion of radiation therapy, patients received TLR9 agonist SD-101 IT on day 2 and on days 9, 16, 23, 30 and 37. Patients also received ibrutinib PO daily beginning on day 9 for 96 weeks or in the absence of disease progression or unexpected toxicity. | 11 |
| Phase II -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) Patients underwent radiation therapy on days 1 and 2. Within 12 hours of the completion of radiation therapy, patients received TLR9 agonist SD-101 IT on day 2 and on days 9, 16, 23, 30 and 37. Patients also received ibrutinib PO daily beginning on day 9 for 96 weeks or in the absence of disease progression or unexpected toxicity. | 10 |
| Total | 21 |
Baseline characteristics
| Characteristic | Phase 1b -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) | Phase II -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 5 Participants | 3 Participants | 8 Participants |
| Age, Categorical Between 18 and 65 years | 6 Participants | 7 Participants | 13 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 11 Participants | 10 Participants | 21 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 9 Participants | 9 Participants | 18 Participants |
| Region of Enrollment United States | 11 participants | 10 participants | 21 participants |
| Sex: Female, Male Female | 4 Participants | 5 Participants | 9 Participants |
| Sex: Female, Male Male | 7 Participants | 5 Participants | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 20 |
| other Total, other adverse events | 20 / 20 |
| serious Total, serious adverse events | 8 / 20 |
Outcome results
Primary
Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib)
Dose-limiting toxicity was continuously throughout the trial. Adverse event information was collected at each visit. Safety labs were collected on week 2, 4, 6, 12 and every 12 weeks thereafter until the final study visit.
Time frame: Up to 24 months
Population: Participants who received treatment are included in the analysis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Phase 1b -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) | Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) | 1 Participants |
| Phase II -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) | Number of Dose-limiting Toxicity Assessed Using Common Terminology Criteria for Adverse Events Version 4.0 (Phase Ib) | 0 Participants |
Primary
Tumor Response Rates (Phase II)
Tumor response rate of intratumoral SD 101 in combination with ibrutinib and radiation in subjects will be assessed. Tumor response rates (complete response, partial response) will be calculated based on the Lugano classification for low-grade B-cell lymphomas.
Time frame: Up to 24 months
Population: Participants who received treatment are included in the analysis
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) | Tumor Response Rates (Phase II) | Partial Response | 4 Participants |
| Phase 1b -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) | Tumor Response Rates (Phase II) | Complete Response | 0 Participants |
| Phase II -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) | Tumor Response Rates (Phase II) | Complete Response | 1 Participants |
| Phase II -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) | Tumor Response Rates (Phase II) | Partial Response | 5 Participants |
Secondary
Progression-free Survival (Phase II)
Progression free Survival is defined as the time elapsed between treatment initiation (Day 1) and tumor progression or death from any cause. Progression will be defined using the Lugano Classification. This outcome will be measured on any individual who has received at least one intratumoral injection of SD 101 at the recommended phase 2 dose level.
Time frame: Up to 24 months
Population: Participants who received treatment are included in the analysis
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) | Progression-free Survival (Phase II) | 11 Months |
| Phase II -SD-101 3mg: Treatment (Radiation Therapy, TLR9 Agonist SD-101, Ibrutinib) | Progression-free Survival (Phase II) | 11 Months |